5.91
price up icon1.81%   +0.10
 
loading
Angiodynamic Inc stock is currently priced at $5.91, with a 24-hour trading volume of 50,604. It has seen a +1.81% increased in the last 24 hours and a +0.77% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $6.00 pivot point. If it approaches the $5.57 support level, significant changes may occur.
Previous Close:
$5.81
Open:
$5.81
24h Volume:
50,604
Market Cap:
$232.72M
Revenue:
$324.01M
Net Income/Loss:
$-192.37M
P/E Ratio:
36.94
EPS:
0.16
Net Cash Flow:
$-23.46M
1W Performance:
-5.51%
1M Performance:
+0.77%
6M Performance:
-7.00%
1Y Performance:
-28.91%
1D Range:
Value
$5.81
$5.96
52W Range:
Value
$5.26
$11.38

Angiodynamic Inc Stock (ANGO) Company Profile

Name
Name
Angiodynamic Inc
Name
Phone
518-795-1400
Name
Address
14 Plaza Drive, Latham
Name
Employee
1,145
Name
Twitter
@angiodynamics
Name
Next Earnings Date
2024-04-04
Name
Latest SEC Filings
Name
ANGO's Discussions on Twitter

Angiodynamic Inc Stock (ANGO) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-17-23 Downgrade Raymond James Strong Buy → Outperform
Oct-15-21 Upgrade Canaccord Genuity Hold → Buy
Aug-20-21 Initiated Oppenheimer Perform
Nov-25-20 Upgrade Raymond James Mkt Perform → Strong Buy
Apr-08-20 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Apr-01-19 Upgrade KeyBanc Capital Markets Sector Weight → Overweight
Apr-03-18 Upgrade Raymond James Mkt Perform → Outperform
Jan-05-18 Downgrade Craig Hallum Buy → Hold
Apr-07-17 Reiterated Cantor Fitzgerald Overweight
Mar-30-17 Downgrade KeyBanc Capital Mkts Overweight → Sector Weight
Feb-08-17 Initiated Barclays Equal Weight
Nov-04-16 Initiated Cantor Fitzgerald Buy
Apr-08-16 Resumed Piper Jaffray Neutral
Jan-08-16 Reiterated Canaccord Genuity Buy
Nov-10-15 Downgrade Raymond James Outperform → Mkt Perform
Jul-24-15 Initiated KeyBanc Capital Mkts Overweight
Jun-19-14 Upgrade Canaccord Genuity Hold → Buy
Oct-09-12 Reiterated Canaccord Genuity Hold
Jun-25-12 Downgrade Canaccord Genuity Buy → Hold
Jul-15-11 Upgrade Canaccord Genuity Hold → Buy
Jul-15-11 Upgrade Stifel Nicolaus Hold → Buy
Jun-14-11 Downgrade Wedbush Neutral → Underperform
Sep-08-10 Reiterated Wedbush Neutral
View All

Angiodynamic Inc Stock (ANGO) Financials Data

Angiodynamic Inc (ANGO) Revenue 2024

ANGO reported a revenue (TTM) of $324.01 million for the quarter ending February 29, 2024, a -3.19% decline year-over-year.
loading

Angiodynamic Inc (ANGO) Net Income 2024

ANGO net income (TTM) was -$192.37 million for the quarter ending February 29, 2024, a -416.55% decrease year-over-year.
loading

Angiodynamic Inc (ANGO) Cash Flow 2024

ANGO recorded a free cash flow (TTM) of -$23.46 million for the quarter ending February 29, 2024, a -101.38% decrease year-over-year.
loading

Angiodynamic Inc (ANGO) Earnings per Share 2024

ANGO earnings per share (TTM) was -$4.78 for the quarter ending February 29, 2024, a -408.51% decline year-over-year.
loading

Angiodynamic Inc Stock (ANGO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Trowbridge Stephen A
EVP and CFO
Jul 19 '23
Option Exercise
0.00
8,769
0
123,364
Centea Scott
SVP/GM, VIT
Jul 19 '23
Option Exercise
0.00
3,415
0
61,543
Campbell Chad Thomas
SVP/GM, Vascular Access
Jul 19 '23
Option Exercise
0.00
3,900
0
51,409
Helsel Dave
SVP Global Operations and R&D
Jul 19 '23
Option Exercise
0.00
4,371
0
32,660
Clemmer James C
President and CEO
Jul 19 '23
Option Exercise
0.00
31,572
0
560,638
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. It also offers thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; and Asclera injection for treating uncomplicated spider and reticular veins of the lower extremities. Further, it provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation system; and radiofrequency ablation products for ablating solid cancerous or benign tumors. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
medical_instruments_supplies ATR
$146.87
price up icon 2.48%
medical_instruments_supplies TFX
$209.56
price up icon 1.38%
medical_instruments_supplies COO
$89.76
price up icon 0.99%
$76.67
price up icon 0.91%
medical_instruments_supplies BAX
$40.87
price up icon 1.86%
medical_instruments_supplies WST
$357.38
price down icon 0.86%
Cap:     |  Volume (24h):